{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,21]],"date-time":"2026-09-21T17:05:40Z","timestamp":1790010340203,"version":"4.0.1"},"reference-count":63,"publisher":"Springer Science and Business Media LLC","license":[{"start":{"date-parts":[[2024,9,25]],"date-time":"2024-09-25T00:00:00Z","timestamp":1727222400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2024,9,25]],"date-time":"2024-09-25T00:00:00Z","timestamp":1727222400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Ann Hematol"],"DOI":"10.1007\/s00277-024-06013-2","type":"journal-article","created":{"date-parts":[[2024,9,25]],"date-time":"2024-09-25T06:05:29Z","timestamp":1727244329000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":5,"title":["Interstitial lung disease presents with varying characteristics in patients with non-Hodgkin lymphoma undergoing rituximab-containing therapies"],"prefix":"10.1007","author":[{"given":"Wailong","family":"Zou","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jia","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yulin","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zhe","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rui","family":"Yang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yaxin","family":"Yan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Weihua","family":"Zhu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Feng","family":"Ma","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Piping","family":"Jiang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yumin","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xinjun","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jichao","family":"Chen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2024,9,25]]},"reference":[{"key":"6013_CR1","doi-asserted-by":"publisher","first-page":"233","DOI":"10.1111\/j.1365-2141.2009.07718.x","volume":"146","author":"V McDonald","year":"2009","unstructured":"McDonald V, Leandro M (2009) Rituximab in non-haematological disorders of adults and its mode of action. Br J Haematol 146:233\u2013246. https:\/\/doi.org\/10.1111\/j.1365-2141.2009.07718.x","journal-title":"Br J Haematol"},{"key":"6013_CR2","doi-asserted-by":"publisher","first-page":"714","DOI":"10.1002\/pds.1587","volume":"17","author":"V Gonz\u00e1lez","year":"2008","unstructured":"Gonz\u00e1lez V, Salgueiro E, Jimeno FJ, Hidalgo A, Rubio T, Manso G (2008) Post-marketing safety of antineoplasic monoclonal antibodies: rituximab and trastuzumab. Pharmacoepidemiol Drug Saf 17:714\u2013721. https:\/\/doi.org\/10.1002\/pds.1587","journal-title":"Pharmacoepidemiol Drug Saf"},{"key":"6013_CR3","doi-asserted-by":"publisher","first-page":"448","DOI":"10.4143\/crt.2014.034","volume":"47","author":"S Park","year":"2015","unstructured":"Park S, Kang CI, Chung DR, Peck KR, Kim WS, Kim SJ (2015) Clinical significance of non-neutropenic fever in the management of diffuse large B-cell lymphoma patients treated with rituximab-CHOP: comparison with febrile neutropenia and risk factor analysis. Cancer Res Treat 47:448\u2013457. https:\/\/doi.org\/10.4143\/crt.2014.034","journal-title":"Cancer Res Treat"},{"key":"6013_CR4","doi-asserted-by":"publisher","first-page":"916","DOI":"10.1002\/ajh.20910","volume":"82","author":"SA Wagner","year":"2007","unstructured":"Wagner SA, Mehta AC, Laber DA (2007) Rituximab-induced interstitial lung disease. Am J Hematol 82:916\u2013919. https:\/\/doi.org\/10.1002\/ajh.20910","journal-title":"Am J Hematol"},{"key":"6013_CR5","doi-asserted-by":"publisher","first-page":"681","DOI":"10.1183\/09031936.00080209","volume":"35","author":"H Liot\u00e9","year":"2010","unstructured":"Liot\u00e9 H, Liot\u00e9 F, S\u00e9roussi B, Mayaud C, Cadranel J (2010) Rituximab-induced lung disease: a systematic literature review. Eur Respir J 35:681\u2013687. https:\/\/doi.org\/10.1183\/09031936.00080209","journal-title":"Eur Respir J"},{"key":"6013_CR6","doi-asserted-by":"publisher","first-page":"141","DOI":"10.1007\/s00277-017-3160-1","volume":"97","author":"T Zhou","year":"2018","unstructured":"Zhou T, Shen Q, Peng H et al (2018) Incidence of interstitial pneumonitis in non-hodgkin\u2019s lymphoma patients receiving immunochemotherapy with pegylated liposomal doxorubicin and rituximab. Ann Hematol 97:141\u2013147. https:\/\/doi.org\/10.1007\/s00277-017-3160-1","journal-title":"Ann Hematol"},{"key":"6013_CR7","doi-asserted-by":"publisher","first-page":"653","DOI":"10.1093\/rheumatology\/ker290","volume":"51","author":"AV Hadjinicolaou","year":"2012","unstructured":"Hadjinicolaou AV, Nisar MK, Parfrey H, Chilvers ER, Ost\u00f6r AJK (2012) Non-infectious pulmonary toxicity of Rituximab: a systematic review. Rheumatology (Oxford) 51:653\u2013662. https:\/\/doi.org\/10.1093\/rheumatology\/ker290","journal-title":"Rheumatology (Oxford)"},{"key":"6013_CR8","doi-asserted-by":"publisher","first-page":"393","DOI":"10.1007\/s12185-008-0066-7","volume":"87","author":"D Ennishi","year":"2008","unstructured":"Ennishi D, Terui Y, Yokoyama M et al (2008) Increased incidence of interstitial pneumonia by CHOP combined with rituximab. Int J Hematol 87:393\u2013397. https:\/\/doi.org\/10.1007\/s12185-008-0066-7","journal-title":"Int J Hematol"},{"key":"6013_CR9","doi-asserted-by":"publisher","first-page":"7614","DOI":"10.1200\/JCO.2005.02.7243","volume":"23","author":"WG Martin","year":"2005","unstructured":"Martin WG, Ristow KM, Habermann TM, Colgan JP, Witzig TE, Ansell SM (2005) Bleomycin pulmonary toxicity has a negative impact on the outcome of patients with Hodgkin\u2019s lymphoma. J Clin Oncol 23:7614\u20137620. https:\/\/doi.org\/10.1200\/JCO.2005.02.7243","journal-title":"J Clin Oncol"},{"key":"6013_CR10","volume-title":"Internal medicine","author":"JB Ge","year":"2013","unstructured":"Ge JB, Xu YJ (2013) Internal medicine. People\u2019s Health Publishing House, Beijing"},{"key":"6013_CR11","volume-title":"Practical interstitial lung disease","author":"HR Cai","year":"2016","unstructured":"Cai HR, Zhang XY, Li HP (2016) Practical interstitial lung disease. People\u2019s Health Publishing House, Beijing"},{"key":"6013_CR12","unstructured":"Antoine MH, Mlika M (2023) Interstitial lung disease. StatPearls Publishing. https:\/\/www.ncbi.nlm.nih.gov\/books\/NBK541084\/. Accessed 26 June 2007"},{"key":"6013_CR13","doi-asserted-by":"publisher","first-page":"137","DOI":"10.1164\/rccm.202306-1113ST","volume":"209","author":"G Raghu","year":"2024","unstructured":"Raghu G, Montesi SB, Silver RM et al (2024) Treatment of systemic sclerosis-associated interstitial lung disease: evidence-based recommendations. An official American Thoracic Society clinical practice guideline. Am J Respir Crit Care Med 209:137\u2013152. https:\/\/doi.org\/10.1164\/rccm.202306-1113ST","journal-title":"Am J Respir Crit Care Med"},{"key":"6013_CR14","doi-asserted-by":"publisher","first-page":"e18","DOI":"10.1164\/rccm.202202-0399ST","volume":"205","author":"G Raghu","year":"2022","unstructured":"Raghu G, Remy-Jardin M, Richeldi L et al (2022) Idiopathic pulmonary fibrosis (an update) and progressive pulmonary fibrosis in adults: an official ATS\/ERS\/JRS\/ALAT clinical practice guideline. Am J Respir Crit Care Med 205:e18\u2013e47. https:\/\/doi10.1164\/rccm.202202-0399ST","journal-title":"Am J Respir Crit Care Med"},{"key":"6013_CR15","doi-asserted-by":"publisher","first-page":"277","DOI":"10.1164\/ajrccm.165.2.ats01","volume":"165","author":"American Thoracic Society, European Respiratory Society","year":"2002","unstructured":"American Thoracic Society, European Respiratory Society (2002) American Thoracic Society\/European Respiratory Society international multidisciplinary consensus classification of the idiopathic interstitial pneumonias. This joint statement of the American Thoracic Society (ATS), and the European Respiratory Society (ERS) was adopted by the ATS board of directors, June 2001 and by the ERS Executive Committee, June 2001. Am J Respir Crit Care Med 165:277\u2013304. https:\/\/doi.org\/10.1164\/ajrccm.165.2.ats01","journal-title":"Am J Respir Crit Care Med"},{"key":"6013_CR16","doi-asserted-by":"publisher","first-page":"649","DOI":"10.1097\/00000421-198212000-00014","volume":"5","author":"MM Oken","year":"1982","unstructured":"Oken MM, Creech RH, Tormey DC et al (1982) Toxicity and response criteria of the Eastern Cooperative Oncology Group. Am J Clin Oncol 5:649\u2013655. https:\/\/doi.org\/10.1097\/00000421-198212000-00014","journal-title":"Am J Clin Oncol"},{"key":"6013_CR17","doi-asserted-by":"publisher","first-page":"987","DOI":"10.1056\/NEJM199309303291402","volume":"329","author":"International Non-Hodgkin\u2019s Lymphoma Prognostic Factors Project","year":"1993","unstructured":"International Non-Hodgkin\u2019s Lymphoma Prognostic Factors Project (1993) A predictive model for aggressive non-hodgkin\u2019s lymphoma. N Engl J Med 329:987\u2013994. https:\/\/doi.org\/10.1056\/NEJM199309303291402","journal-title":"N Engl J Med"},{"key":"6013_CR18","doi-asserted-by":"publisher","first-page":"298","DOI":"10.1016\/S0140-6736(16)32407-2","volume":"390","author":"JO Armitage","year":"2017","unstructured":"Armitage JO, Gascoyne RD, Lunning MA, Cavalli F (2017) Non-hodgkin lymphoma. Lancet 390:298\u2013310. https:\/\/doi.org\/10.1016\/S0140-6736(16)32407-2","journal-title":"Lancet"},{"key":"6013_CR19","doi-asserted-by":"publisher","first-page":"288","DOI":"10.1056\/NEJMc1505197","volume":"373","author":"M Nishino","year":"2015","unstructured":"Nishino M, Sholl LM, Hodi FS, Hatabu H, Ramaiya NH (2015) Anti-PD-1-related pneumonitis during cancer immunotherapy. N Engl J Med 373:288\u2013290. https:\/\/doi.org\/10.1056\/NEJMc1505197","journal-title":"N Engl J Med"},{"key":"6013_CR20","doi-asserted-by":"publisher","first-page":"241","DOI":"10.19401\/j.cnki.1007-3639.2021.04.001","volume":"31","author":"ZH Jian","year":"2021","unstructured":"Jian ZH, Weina SH, Dongmei JI, Leiping WA, Chengcheng GO, Xichun HU (2021) FUSCC criteria for the management of targeted drug\u2043induced interstitial lung disease in solid tumors. China Oncol 31:241\u2013249. https:\/\/doi.org\/10.19401\/j.cnki.1007-3639.2021.04.001","journal-title":"China Oncol"},{"key":"6013_CR21","doi-asserted-by":"publisher","first-page":"163","DOI":"10.1016\/j.ejca.2015.10.015","volume":"53","author":"M Nishino","year":"2016","unstructured":"Nishino M, Brais LK, Brooks NV, Hatabu H, Kulke MH, Ramaiya NH (2016) Drug-related pneumonitis during mammalian target of rapamycin inhibitor therapy in patients with neuroendocrine tumors: a radiographic pattern-based approach. Eur J Cancer 53:163\u2013170. https:\/\/doi.org\/10.1016\/j.ejca.2015.10.015","journal-title":"Eur J Cancer"},{"key":"6013_CR22","doi-asserted-by":"publisher","first-page":"1077","DOI":"10.1634\/theoncologist.2015-0033","volume":"20","author":"M Nishino","year":"2015","unstructured":"Nishino M, Boswell EN, Hatabu H, Ghobrial IM, Ramaiya NH (2015) Drug-related pneumonitis during mammalian target of rapamycin inhibitor therapy: radiographic pattern-based approach in Waldenstrom macroglobulinemia as a paradigm. Oncologist 20:1077\u20131083. https:\/\/doi.org\/10.1634\/theoncologist.2015-0033","journal-title":"Oncologist"},{"key":"6013_CR23","doi-asserted-by":"publisher","first-page":"733","DOI":"10.1164\/rccm.201308-1483ST","volume":"188","author":"WD Travis","year":"2013","unstructured":"Travis WD, Costabel U, Hansell DM et al (2013) An official American Thoracic Society\/European Respiratory Society statement: update of the international multidisciplinary classification of the idiopathic interstitial pneumonias. Am J Respir Crit Care Med 188:733\u2013748. https:\/\/doi.org\/10.1164\/rccm.201308-1483ST","journal-title":"Am J Respir Crit Care Med"},{"key":"6013_CR24","doi-asserted-by":"publisher","first-page":"360","DOI":"10.1016\/j.rppnen.2017.10.003","volume":"23","author":"M Costa e Silva","year":"2017","unstructured":"Costa e Silva M, Rolo R (2017) The role of bronchoalveolar lavage in interstitial lung diseases. Rev Port Pneumol (2006) 23:360\u2013362. https:\/\/doi.org\/10.1016\/j.rppnen.2017.10.003","journal-title":"Rev Port Pneumol (2006)"},{"key":"6013_CR25","unstructured":"National Institutes of Health (2010) Common terminology criteria for adverse events (CTCAE), v.5.0. https:\/\/ctep.cancer.gov\/protocoldevelopment\/electronic_applications\/ctc.htm. Accessed 26 June 2007"},{"key":"6013_CR26","doi-asserted-by":"publisher","first-page":"932","DOI":"10.1002\/prca.201400001","volume":"8","author":"C Landi","year":"2014","unstructured":"Landi C, Bargagli E, Carleo A et al (2014) A system biology study of BALF from patients affected by idiopathic pulmonary fibrosis (IPF) and healthy controls. Proteom Clin Appl 8:932\u2013950. https:\/\/doi.org\/10.1002\/prca.201400001","journal-title":"Proteom Clin Appl"},{"key":"6013_CR27","doi-asserted-by":"publisher","first-page":"54","DOI":"10.1111\/joim.12973","volume":"287","author":"BC Frye","year":"2020","unstructured":"Frye BC, Schupp JC, Rothe ME et al (2020) The value of bronchoalveolar lavage for discrimination between healthy and diseased individuals. J Intern Med 287:54\u201365. https:\/\/doi.org\/10.1111\/joim.12973","journal-title":"J Intern Med"},{"key":"6013_CR28","doi-asserted-by":"publisher","first-page":"524","DOI":"10.1164\/rccm.201706-1097LE","volume":"197","author":"C Langelier","year":"2018","unstructured":"Langelier C, Zinter MS, Kalantar K et al (2018) Metagenomic sequencing detects respiratory pathogens in hematopoietic cellular transplant patients. Am J Respir Crit Care Med 197:524\u2013528. https:\/\/doi.org\/10.1164\/rccm.201706-1097LE","journal-title":"Am J Respir Crit Care Med"},{"key":"6013_CR29","doi-asserted-by":"publisher","first-page":"314","DOI":"10.3760\/j:issn:0376-2491.2001.05.027","volume":"81","author":"Ministry of Health of the People\u2019s Republic of China","year":"2001","unstructured":"Ministry of Health of the People\u2019s Republic of China (2001) Diagnostic standards for hospital infection (trial). Chin Med J (Engl) 81:314\u2013320. https:\/\/doi.org\/10.3760\/j:issn:0376-2491.2001.05.027","journal-title":"Chin Med J (Engl)"},{"key":"6013_CR30","doi-asserted-by":"publisher","first-page":"e56","DOI":"10.1093\/cid\/cir073","volume":"52","author":"AG Freifeld","year":"2011","unstructured":"Freifeld AG, Bow EJ, Sepkowitz KA et al (2011) Clinical practice guideline for the use of antimicrobial agents in neutropenic patients with cancer: 2010 update by the Infectious Diseases Society of America. Clin Infect Dis 52:e56\u2013e93. https:\/\/doi.org\/10.1093\/cid\/cir073","journal-title":"Clin Infect Dis"},{"key":"6013_CR31","doi-asserted-by":"publisher","first-page":"100404","DOI":"10.1016\/j.esmoop.2022.100404","volume":"7","author":"P Conte","year":"2022","unstructured":"Conte P, Ascierto PA, Patelli G et al (2022) Drug-induced interstitial lung disease during cancer therapies: expert opinion on diagnosis and treatment. ESMO Open 7:100404. https:\/\/doi.org\/10.1016\/j.esmoop.2022.100404","journal-title":"ESMO Open"},{"key":"6013_CR32","doi-asserted-by":"publisher","first-page":"133","DOI":"10.1007\/s00277-017-3157-9","volume":"97","author":"WP Liu","year":"2018","unstructured":"Liu WP, Wang XP, Zheng W et al (2018) Incidence, clinical characteristics, and outcome of interstitial pneumonia in patients with lymphoma. Ann Hematol 97:133\u2013139. https:\/\/doi.org\/10.1007\/s00277-017-3157-9","journal-title":"Ann Hematol"},{"key":"6013_CR33","doi-asserted-by":"publisher","first-page":"1659","DOI":"10.3109\/10428194.2014.963075","volume":"56","author":"G Salmasi","year":"2015","unstructured":"Salmasi G, Li M, Sivabalasundaram V et al (2015) Incidence of pneumonitis in patients with non-hodgkin lymphoma receiving chemoimmunotherapy with rituximab. Leuk Lymphoma 56:1659\u20131664. https:\/\/doi.org\/10.3109\/10428194.2014.963075","journal-title":"Leuk Lymphoma"},{"key":"6013_CR34","doi-asserted-by":"publisher","first-page":"936","DOI":"10.3969\/j.issn.1007-3969.2014.12.010","volume":"24","author":"WA Qian","year":"2015","unstructured":"Qian WA, Yu-Fen ZH, Rong-Fei JI (2015) The risk factors and clinical features of interstitial pneumonia in B-cell non-hodgkin\u2019s lymphoma patients who were treated with rituximab-CHOP regimen. China Oncol 24:936\u2013943. https:\/\/doi.org\/10.3969\/j.issn.1007-3969.2014.12.010","journal-title":"China Oncol"},{"key":"6013_CR35","doi-asserted-by":"publisher","first-page":"2102776","DOI":"10.1183\/13993003.02776-2021","volume":"60","author":"P Spagnolo","year":"2022","unstructured":"Spagnolo P, Bonniaud P, Rossi G, Sverzellati N, Cottin V (2022) Drug-induced interstitial lung disease. Eur Respir J 60:2102776. https:\/\/doi.org\/10.1183\/13993003.02776-2021","journal-title":"Eur Respir J"},{"key":"6013_CR36","doi-asserted-by":"publisher","first-page":"1142016","DOI":"10.3389\/fphar.2023.1142016","volume":"14","author":"H Li","year":"2023","unstructured":"Li H, Zheng Y, Xu P et al (2023) Comparison of pneumonitis risk between immunotherapy alone and in combination with chemotherapy: an observational, retrospective pharmacovigilance study. Front Pharmacol 14:1142016. https:\/\/doi.org\/10.3389\/fphar.2023.1142016","journal-title":"Front Pharmacol"},{"key":"6013_CR37","doi-asserted-by":"publisher","first-page":"805","DOI":"10.1080\/17425255.2022.2162383","volume":"18","author":"WP Yong","year":"2022","unstructured":"Yong WP, Teo FS, Teo LL et al (2022) Clinical best practices in optimal monitoring, early diagnosis, and effective management of antibody-drug conjugate-induced interstitial lung disease or pneumonitis: a multidisciplinary team approach in Singapore. Expert Opin Drug Metab Toxicol 18:805\u2013815. https:\/\/doi.org\/10.1080\/17425255.2022.2162383","journal-title":"Expert Opin Drug Metab Toxicol"},{"key":"6013_CR38","doi-asserted-by":"publisher","first-page":"842","DOI":"10.1016\/j.chest.2017.03.033","volume":"152","author":"N Azadeh","year":"2017","unstructured":"Azadeh N, Limper AH, Carmona EM, Ryu JH (2017) The role of infection in interstitial lung diseases: a review. Chest 152:842\u2013852. https:\/\/doi.org\/10.1016\/j.chest.2017.03.033","journal-title":"Chest"},{"key":"6013_CR39","doi-asserted-by":"publisher","first-page":"260","DOI":"10.1016\/j.resinv.2013.09.001","volume":"51","author":"K Kubo","year":"2013","unstructured":"Kubo K, Azuma A, Kanazawa M et al (2013) Consensus statement for the diagnosis and treatment of drug-induced lung injuries. Respir Investig 51:260\u2013277. https:\/\/doi.org\/10.1016\/j.resinv.2013.09.001","journal-title":"Respir Investig"},{"key":"6013_CR40","doi-asserted-by":"publisher","first-page":"265","DOI":"10.1164\/rccm.201604-0801CI","volume":"194","author":"HR Collard","year":"2016","unstructured":"Collard HR, Ryerson CJ, Corte TJ et al (2016) Acute exacerbation of idiopathic pulmonary fibrosis. An International Working Group report. Am J Respir Crit Care Med 194:265\u2013275. https:\/\/doi.org\/10.1164\/rccm.201604-0801CI","journal-title":"Am J Respir Crit Care Med"},{"key":"6013_CR41","doi-asserted-by":"publisher","first-page":"2375","DOI":"10.1093\/annonc\/mdv383","volume":"26","author":"J Naidoo","year":"2015","unstructured":"Naidoo J, Page DB, Li BT et al (2015) Toxicities of the anti-PD-1 and anti-PD-L1 immune checkpoint antibodies. Ann Oncol 26:2375\u20132391. https:\/\/doi.org\/10.1093\/annonc\/mdv383","journal-title":"Ann Oncol"},{"key":"6013_CR42","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1007\/s11596-022-2693-2","volume":"43","author":"HP Dai","year":"2023","unstructured":"Dai HP, Ma F, Ren YH, Chen SS, Li YQ (2023) Expert consensus on the diagnosis and treatment of anticancer drug-induced interstitial lung disease. Curr Med Sci 43:1\u201312. https:\/\/doi.org\/10.1007\/s11596-022-2693-2","journal-title":"Curr Med Sci"},{"key":"6013_CR43","doi-asserted-by":"publisher","first-page":"1700050","DOI":"10.1183\/13993003.00050-2017","volume":"50","author":"M Delaunay","year":"2017","unstructured":"Delaunay M, Cadranel J, Lusque A et al (2017) Immune-checkpoint inhibitors associated with interstitial lung disease in cancer patients. Eur Respir J 50:1700050. https:\/\/doi.org\/10.1183\/13993003.00050-2017","journal-title":"Eur Respir J"},{"key":"6013_CR44","doi-asserted-by":"publisher","first-page":"1416","DOI":"10.1016\/j.chest.2018.08.1048","volume":"154","author":"K Suresh","year":"2018","unstructured":"Suresh K, Naidoo J, Lin CT, Danoff S (2018) Immune checkpoint immunotherapy for non-small cell lung cancer: benefits and pulmonary toxicities. Chest 154:1416\u20131423. https:\/\/doi.org\/10.1016\/j.chest.2018.08.1048","journal-title":"Chest"},{"key":"6013_CR45","doi-asserted-by":"publisher","first-page":"712","DOI":"10.6004\/jnccn.2018.7268","volume":"17","author":"J Naidoo","year":"2019","unstructured":"Naidoo J, Zhang J, Lipson EJ et al (2019) A multidisciplinary toxicity team for cancer immunotherapy\u2013related adverse events. J Natl Compr Canc Netw 17:712\u2013720. https:\/\/doi.org\/10.6004\/jnccn.2018.7268","journal-title":"J Natl Compr Canc Netw"},{"key":"6013_CR46","doi-asserted-by":"publisher","first-page":"e97","DOI":"10.1016\/j.chest.2021.03.066","volume":"160","author":"ER Fern\u00e1ndez P\u00e9rez","year":"2021","unstructured":"Fern\u00e1ndez P\u00e9rez ER, Travis WD, Lynch DA et al (2021) Diagnosis and evaluation of hypersensitivity pneumonitis: CHEST guideline and expert panel report. Chest 160:e97\u2013e156. https:\/\/doi.org\/10.1016\/j.chest.2021.03.066","journal-title":"Chest"},{"key":"6013_CR47","doi-asserted-by":"publisher","first-page":"511","DOI":"10.1183\/09031936.05.00035005","volume":"26","author":"J Wanger","year":"2005","unstructured":"Wanger J, Clausen JL, Coates A et al (2005) Standardisation of the measurement of lung volumes. Eur Respir J 26:511\u2013522. https:\/\/doi.org\/10.1183\/09031936.05.00035005","journal-title":"Eur Respir J"},{"key":"6013_CR48","doi-asserted-by":"publisher","first-page":"2201519","DOI":"10.1183\/13993003.01519-2022","volume":"62","author":"NR Bhakta","year":"2023","unstructured":"Bhakta NR, McGowan A, Ramsey KA et al (2023) European Respiratory Society\/American Thoracic Society technical statement: standardisation of the measurement of lung volumes, 2023 update. Eur Respir J 62:2201519. https:\/\/doi.org\/10.1183\/13993003.01519-2022","journal-title":"Eur Respir J"},{"key":"6013_CR49","doi-asserted-by":"publisher","first-page":"11","DOI":"10.1024\/0040-5930\/a000749","volume":"73","author":"S Berezowska","year":"2016","unstructured":"Berezowska S, P\u00f6llinger A (2016) [Interstitial pneumonias-histopathological and radiological correlation] [article in German]. Ther Umsch 73:11\u201317. https:\/\/doi.org\/10.1024\/0040-5930\/a000749","journal-title":"Ther Umsch"},{"key":"6013_CR50","doi-asserted-by":"publisher","first-page":"807","DOI":"10.1046\/j.1365-2141.2001.03166.x","volume":"115","author":"LE van der Kolk","year":"2001","unstructured":"van der Kolk LE, Grillo-L\u00f3pez AJ, Baars JW, Hack CE, Van Oers MH (2001) Complement activation plays a key role in the side-effects of rituximab treatment. Br J Haematol 115:807\u2013811. https:\/\/doi.org\/10.1046\/j.1365-2141.2001.03166.x","journal-title":"Br J Haematol"},{"key":"6013_CR51","doi-asserted-by":"publisher","first-page":"e9623","DOI":"10.7717\/peerj.9623","volume":"8","author":"P Zhang","year":"2020","unstructured":"Zhang P, Chen Y, Li SY et al (2020) Metagenomic next-generation sequencing for the clinical diagnosis and prognosis of acute respiratory distress syndrome caused by severe pneumonia: a retrospective study. PeerJ 8:e9623. https:\/\/doi.org\/10.7717\/peerj.9623","journal-title":"PeerJ"},{"key":"6013_CR52","doi-asserted-by":"publisher","first-page":"1778","DOI":"10.1080\/10428190802270886","volume":"49","author":"X Liu","year":"2008","unstructured":"Liu X, Hong XN, Gu YJ, Wang BY, Luo ZG, Cao J (2008) Interstitial pneumonitis during rituximab-containing chemotherapy for non-hodgkin lymphoma. Leuk Lymphoma 49:1778\u20131783. https:\/\/doi.org\/10.1080\/10428190802270886","journal-title":"Leuk Lymphoma"},{"key":"6013_CR53","doi-asserted-by":"publisher","first-page":"378","DOI":"10.1038\/sj.thj.6200133","volume":"2","author":"J Bienvenu","year":"2001","unstructured":"Bienvenu J, Chvetzoff R, Salles G et al (2001) Tumor necrosis factor alpha release is a major biological event associated with rituximab treatment. Hematol J 2:378\u2013384. https:\/\/doi.org\/10.1038\/sj.thj.6200133","journal-title":"Hematol J"},{"key":"6013_CR54","doi-asserted-by":"publisher","first-page":"516","DOI":"10.1097\/01.TP.0000074700.30536.76","volume":"76","author":"HS Alho","year":"2003","unstructured":"Alho HS, Maasilta PK, Harjula ALJ, H\u00e4mm\u00e4inen P, Salminen J, Salminen US (2003) Tumor necrosis factor-alpha in a porcine bronchial model of obliterative bronchiolitis. Transplantation 76:516\u2013523. https:\/\/doi.org\/10.1097\/01.TP.0000074700.30536.76","journal-title":"Transplantation"},{"key":"6013_CR55","doi-asserted-by":"publisher","first-page":"76","DOI":"10.1016\/j.ejim.2021.04.005","volume":"89","author":"L Bergantini","year":"2021","unstructured":"Bergantini L, D\u2019Alessandro M, Cameli P et al (2021) Integrated approach to bronchoalveolar lavage cytology to distinguish interstitial lung diseases. Eur J Intern Med 89:76\u201380. https:\/\/doi.org\/10.1016\/j.ejim.2021.04.005","journal-title":"Eur J Intern Med"},{"key":"6013_CR56","doi-asserted-by":"publisher","first-page":"567","DOI":"10.2147\/IDR.S235182","volume":"13","author":"J Huang","year":"2020","unstructured":"Huang J, Jiang E, Yang D et al (2020) Metagenomic next-generation sequencing versus traditional pathogen detection in the diagnosis of peripheral pulmonary infectious lesions. Infect Drug Resist 13:567\u2013576. https:\/\/doi.org\/10.2147\/IDR.S235182","journal-title":"Infect Drug Resist"},{"key":"6013_CR57","doi-asserted-by":"publisher","unstructured":"Postow MA (2015) Managing immune checkpoint-blocking antibody side effects. Am Soc Clin Oncol Educ Book 76\u201383. https:\/\/doi.org\/10.14694\/EdBook_AM.2015.35.76","DOI":"10.14694\/EdBook_AM.2015.35.76"},{"key":"6013_CR58","doi-asserted-by":"publisher","first-page":"iv119","DOI":"10.1093\/annonc\/mdx225","volume":"4","author":"JBAG Haanen","year":"2017","unstructured":"Haanen JBAG, Carbonnel F, Robert C et al (2017) Management of toxicities from immunotherapy: ESMO clinical practice guidelines for diagnosis, treatment and follow-up. Ann Oncol 28 Supplement 4:iv119\u2013iv142. https:\/\/doi.org\/10.1093\/annonc\/mdx225","journal-title":"Ann Oncol 28 Supplement"},{"key":"6013_CR59","doi-asserted-by":"publisher","first-page":"22","DOI":"10.2307\/3578635","volume":"136","author":"HE Ward","year":"1993","unstructured":"Ward HE, Kemsley L, Davies L, Holecek M, Berend N (1993) The effect of steroids on radiation-induced lung disease in the rat. Radiat Res 136:22\u201328. https:\/\/doi.org\/10.2307\/3578635","journal-title":"Radiat Res"},{"key":"6013_CR60","doi-asserted-by":"publisher","first-page":"1088","DOI":"10.1111\/resp.12807","volume":"21","author":"M Hanada","year":"2016","unstructured":"Hanada M, Sakamoto N, Ishimatsu Y et al (2016) Effect of long-term treatment with corticosteroids on skeletal muscle strength, functional exercise capacity and health status in patients with interstitial lung disease. Respirology 21:1088\u20131093. https:\/\/doi.org\/10.1111\/resp.12807","journal-title":"Respirology"},{"key":"6013_CR61","doi-asserted-by":"publisher","first-page":"398","DOI":"10.1177\/1060028014566446","volume":"49","author":"T Sakurada","year":"2015","unstructured":"Sakurada T, Kakiuchi S, Tajima S et al (2015) Characteristics of and risk factors for interstitial lung disease induced by chemotherapy for lung cancer. Ann Pharmacother 49:398\u2013404. https:\/\/doi.org\/10.1177\/1060028014566446","journal-title":"Ann Pharmacother"},{"key":"6013_CR62","doi-asserted-by":"publisher","first-page":"51","DOI":"10.1016\/j.ctrv.2016.02.001","volume":"44","author":"L Spain","year":"2016","unstructured":"Spain L, Diem S, Larkin J (2016) Management of toxicities of immune checkpoint inhibitors. Cancer Treat Rev 44:51\u201360. https:\/\/doi.org\/10.1016\/j.ctrv.2016.02.001","journal-title":"Cancer Treat Rev"},{"key":"6013_CR63","doi-asserted-by":"publisher","first-page":"1334899","DOI":"10.3389\/fimmu.2024.1334899","volume":"15","author":"D Brazel","year":"2024","unstructured":"Brazel D, Grant C, Cabal A, Chen WP, Pinter-Brown L (2024) Baseline immunoglobulin G and immune function in non-hodgkin lymphoma: a retrospective analysis. Front Immunol 15:1334899. https:\/\/doi.org\/10.3389\/fimmu.2024.1334899","journal-title":"Front Immunol"}],"container-title":["Annals of Hematology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00277-024-06013-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s00277-024-06013-2\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00277-024-06013-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,9,25]],"date-time":"2024-09-25T21:39:47Z","timestamp":1727300387000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s00277-024-06013-2"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,9,25]]},"references-count":63,"alternative-id":["6013"],"URL":"https:\/\/doi.org\/10.1007\/s00277-024-06013-2","relation":{},"ISSN":["0939-5555","1432-0584"],"issn-type":[{"value":"0939-5555","type":"print"},{"value":"1432-0584","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,9,25]]},"assertion":[{"value":"1 July 2024","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"15 September 2024","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"25 September 2024","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The study protocol was approved by the Institutional Review Board of the Aerospace Center Hospital (no. 2023-004) and was conducted according to the tenets of the Declaration of Helsinki. The need for informed consent was waived because of the retrospective nature of the study.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"The authors declare no competing interests.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}]}}